Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
A prescription form of omega‐3 fatty acids has been approved by the United States Food and Drug Administration as an adjunct to diet for the treatment of very high triglyceride levels. The active ingredients of omega‐3 fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are responsible for the triglyceride lowering. The prescription product contains a total of 0.84 g of these two active ingredients in every 1‐g capsule of omega‐3 fatty acids. The total EPA and DHA dose recommended for triglyceride lowering is approximately 2–4 g/day Fish oil products containing EPA and DHA are available without a prescription, but the American Heart Association advises that therapy with EPA and DHA to lower very high triglyceride levels should be used only under a physician's care. In patients with triglyceride levels above 500 mg/dl, approximately 4 g/day of EPA and DHA reduces triglyceride levels 45% and very low‐density lipoprotein cholesterol levels by more than 50%. Low‐density lipoprotein cholesterol levels may increase depending on the baseline triglyceride level, but the net effect of EPA and DHA therapy is a reduction in non–high‐density lipoprotein cholesterol level. Alternatively, patients may receive one of the fibrates (gemfibrozil or fenofibrate) or niacin for triglyceride lowering if their triglyceride levels are higher than 500 mg/dl. In controlled trials, prescription omega‐3 fatty acids were well tolerated, with a low rate of both adverse events and treatment‐associated discontinuations. The availability of prescription omega‐3 fatty acids, which ensures consistent quality and purity, should prove to be valuable for the medical management of hypertriglyceridemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · cited 1×
“02).(13) Post hoc analysis showed that the greatest benefit from gemfibrozil treatment was realized by patients with baseline triglyceride levels above 200 mg/dl and HDL levels below 40 mg/dl.”
Background(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812 · cited 1×
“The largest of these, the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione trial, used prescription omega-3 fatty acid (discussed later in this article).(38) In this study, 11,323 patients who had experienced a myocardial infarction within 3 months of study entry were rando…”
MethodFish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Burr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610 · cited 1×
“The best study in this category, the Diet and Reinfarction Trial (DART), randomly assigned 2033 men 4–6 weeks after a myocardial infarction to receive advice on either reduced fat intake, increased fiber intake, or increased fatty-fish intake.(37) Advice concerning fish intake was associated with a 29% reduction in to…”
BackgroundDe Backer, G. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00347-6 · Cited by 2,251
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824 · cited 1×
“In a 10-year follow-up after the conclusion of this study, patients receiving niacin during the study were found to have a statistically significant reduction in total mortality.(20)”
MethodManninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Cited by
Cardiovascular effects of marine omega-3 fatty acids
Saravanan, P., Davidson, N. C., Schmidt, E. B., & Calder, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60445-x · Cited by 511
Circadian Clocks and Feeding Time Regulate the Oscillations and Levels of Hepatic Triglycerides
Adamovich, Y., Rousso-Noori, L., Zwighaft, Z., Neufeld-Cohen, A., Golik, M., Kraut-Cohen, J., Wang, M., Han, X., & Asher, G. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.016 · Cited by 410
Skulas-Ray, A. C., Kris-Etherton, P. M., Harris, W. S., Vanden Heuvel, J. P., Wagner, P. R., & West, S. G. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.003871 · Cited by 280
Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia
Skulas-Ray, A. C., West, S. G., Davidson, M. H., & Kris-Etherton, P. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1237 · Cited by 91
Maki, K. C., McKenney, J. M., Reeves, M. S., Lubin, B. C., & Dicklin, M. R. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.03.078 · Cited by 81
Self-citation
Metadata
- Authors
- McKenney, J. M., & Sica, D.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2007-05
- Volume
- 27
- Issue
- 5
- Pages
- 715-728
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2008131041
- Cited by
- 133
- References
- 24
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia. https://app.cochat.ai/papers/10.1592/phco.27.5.715
- The paper
- McKenney, J. M., & Sica, D. (2007). Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.27.5.715
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.